AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first-line option in combination with Roche's Gazyva (obinutuzumab) as a ...

Q2 2025 Management View CEO Robert A. Michael highlighted that "AbbVie delivered another outstanding quarter with results ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to meet its primary endpoint of progression-free survival ...

For AbbVie, Venclexta brought in revenues of $344 million in 2018, up more than 100% year over year driven by uptake in the second-line plus setting following approval in the United States as well ...

The article AbbVie's Venclexta Notches FDA Win, But Investors Might Want To Temper Enthusiasm originally appeared on Fool.com. Todd Campbell owns shares of Gilead Sciences.

AbbVie announced results from CANOVA, a Phase 3 study evaluating Venclexta (venetoclax) plus dexamethasone (VenDex) for patients with t (11;14)-positive r/r multiple myeloma (MM) who received two ...